RT Journal Article
SR Electronic
T1 Evaluation of the Safety and Efficacy of Combination Chemotherapy with Vinorelbine and Platinum Agents for Patients with Non-small Cell Lung Cancer with Interstitial Lung Disease
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5475
OP 5480
VO 32
IS 12
A1 KENTARO OKUDA
A1 TAKASHI HIROSE
A1 YASUNARI OKI
A1 YASUNORI MURATA
A1 SOJIRO KUSUMOTO
A1 TOMOHIDE SUGIYAMA
A1 HIROO ISHIDA
A1 TAKAO SHIRAI
A1 MASANAO NAKASHIMA
A1 TOSHIMITSU YAMAOKA
A1 TSUKASA OHNISHI
A1 TOHRU OHMORI
YR 2012
UL http://ar.iiarjournals.org/content/32/12/5475.abstract
AB Background: Acute chemotherapy-associated exacerbation of interstitial lung disease (ILD) can occur in patients with non-small cell lung cancer (NSCLC). The safety and efficacy of cytotoxic chemotherapy has not yet been established for NSCLC with ILD. Thus, patients with advanced NSCLC with ILD usually receive only best supportive care. The aim of this study was to assess the safety and efficacy profiles of the combination chemotherapy of vinorelbine and a platinum agent in patients with advanced NSCLC with ILD. Patients and Methods: Nineteen patients with advanced NSCLC with ILD treated with vinorelbine and a platinum agent, either cisplatin or carboplatin, were retrospectively reviewed to examine acute exacerbation of ILD, toxicity, response rate, and survival time. Additionally, possible predictive factors for acute chemotherapy-associated exacerbation of ILD were analyzed. Results: The response rate was 42.1%, the progression-free survival time was 4.4 months, the median survival time was 7.4 months, and the one-year survival rate was 36.8%. Neutropenia was the most frequent grade 3 to 4 toxicity and it occurred in 63.2% of patients. Acute chemotherapy-associated exacerbation of ILD occurred in three patients (15.8%) and caused the death of one of these patients (5.3%). No variables were identified as being predictive factors for acute chemotherapy-associated exacerbation of ILD. Conclusion: The combination chemotherapy with vinorelbine and a platinum agent can be considered as a treatment option for patients with advanced NSCLC with ILD, with careful management after sufficient evaluation of the risks and the benefits.